Michelle M Mielke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1041900/publications.pdf

Version: 2024-02-01

		5268	9103
424	26,897	83	144
papers	citations	h-index	g-index

435	435	435	25785
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
2	Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. Clinical Epidemiology, 2014, 6, 37.	3.0	703
3	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.8	581
4	Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 39, 271-282.	2.6	540
5	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's and Dementia, 2018, 14, 1171-1183.	0.8	468
6	Plasma phosphoâ€tau181 increases with Alzheimer's disease clinical severity and is associated with tauâ€• and amyloidâ€positron emission tomography. Alzheimer's and Dementia, 2018, 14, 989-997.	0.8	386
7	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	7.7	370
8	Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology, 2014, 82, 317-325.	1.1	361
9	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	10.2	360
10	Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimerâ€™s Disease Using Metabolomics. PLoS ONE, 2013, 8, e63644.	2.5	344
11	Assessing the Temporal Relationship Between Cognition and Gait: Slow Gait Predicts Cognitive Decline in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 929-937.	3.6	341
12	Brain Î²-amyloid load approaches a plateau. Neurology, 2013, 80, 890-896.	1.1	335
13	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
14	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.8	310
15	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	7.6	309
16	Age, Sex, andAPOEÎµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511.	9.0	305
17	Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€“89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005.	10.2	297
18	Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia. JAMA Neurology, 2016, 73, 93.	9.0	294

#	Article	IF	Citations
19	The Association of Neuropsychiatric Symptoms in MCI with Incident Dementia and Alzheimer Disease. American Journal of Geriatric Psychiatry, 2013, 21, 685-695.	1.2	264
20	Baseline Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: A Population-Based Study. American Journal of Psychiatry, 2014, 171, 572-581.	7.2	249
21	Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology, 2000, 151, 392-405.	3.1	242
22	Age-specific and sex-specific prevalence of cerebral Î²-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50â€“95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	10.2	241
23	Bloodâ€based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's and Dementia, 2017, 13, 45-58.	0.8	227
24	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	7.4	223
25	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	7.6	222
26	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	7.6	218
27	Evidence for Neurocognitive Plasticity in At-Risk Older Adults: The Experience Corps Program. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1275-1282.	3.6	216
28	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	5.3	215
29	Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. NeuroImage, 2009, 46, 47-55.	4.2	209
30	Progression of Cognitive, Functional, and Neuropsychiatric Symptom Domains in a Population Cohort With Alzheimer Dementia: The Cache County Dementia Progression Study. American Journal of Geriatric Psychiatry, 2011, 19, 532-542.	1.2	198
31	Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy. Journal of the American College of Cardiology, 2020, 75, 2323-2334.	2.8	189
32	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology, 2013, 81, 1732-1740.	1.1	182
33	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	9.0	182
34	Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, 105-113.	0.8	180
35	Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology, 2014, 82, 1132-1141.	1.1	180
36	Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. Alzheimer's and Dementia, 2016, 12, 1186-1196.	0.8	180

#	Article	IF	Citations
37	Serum ceramides increase the risk of Alzheimer disease. Neurology, 2012, 79, 633-641.	1.1	176
38	Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study. PLoS ONE, 2013, 8, e73094.	2.5	176
39	Subjective cognitive decline and risk of MCI. Neurology, 2018, 91, e300-e312.	1.1	176
40	Cardiac Disease Associated With Increased Risk of Nonamnestic Cognitive Impairment. JAMA Neurology, 2013, 70, 374.	9.0	173
41	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	7.6	170
42	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. JAMA Neurology, 2014, 71, 1017.	9.0	160
43	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85.	9.0	160
44	Plasma and CSF neurofilament light. Neurology, 2019, 93, e252-e260.	1.1	160
45	Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency. Psychopharmacology, 1998, 136, 83-90.	3.1	157
46	Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiology of Aging, 2010, 31, 17-24.	3.1	157
47	Brain injury biomarkers are not dependent on Î²â€amyloid in normal elderly. Annals of Neurology, 2013, 73, 472-480.	5.3	155
48	Association of Excessive Daytime Sleepiness With Longitudinal Î²-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672.	9.0	150
49	Recent advances in the application of metabolomics to Alzheimer's Disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1232-1239.	3.8	149
50	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurology, 2017, 74, 1073.	9.0	149
51	Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology, 1999, 147, 135-142.	3.1	146
52	Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology, 2012, 79, 1570-1577.	1.1	146
53	Association of diabetes with amnestic and nonamnestic mild cognitiveÂimpairment. Alzheimer's and Dementia, 2014, 10, 18-26.	0.8	141
54	Sex and gender differences in the causes of dementia: A narrative review. Maturitas, 2014, 79, 196-201.	2.4	139

#	Article	IF	Citations
55	Developing novel bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 109-114.	0.8	138
56	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718.	5.3	136
57	Multimorbidity and Risk of Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2015, 63, 1783-1790.	2.6	135
58	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. Journal of Nuclear Medicine, 2014, 55, 759-764.	5.0	134
59	Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimer's and Dementia, 2010, 6, 378-385.	0.8	133
60	Plasma Sphingomyelins are Associated with Cognitive Progression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 259-269.	2.6	129
61	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
62	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	7.6	126
63	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. Clinical Neuropsychologist, 2013, 27, 1247-1264.	2.3	124
64	Rates of Î²-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology, 2014, 82, 1605-1612.	1.1	119
65	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology, 2018, 75, 970.	9.0	116
66	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	9.0	114
67	Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405.	30.7	114
68	Alterations of the Sphingolipid Pathway in Alzheimerâ€™s Disease: New Biomarkers and Treatment Targets?. NeuroMolecular Medicine, 2010, 12, 331-340.	3.4	112
69	Blood-based biomarkers of microvascular pathology in Alzheimerâ€™s disease. Experimental Gerontology, 2010, 45, 75-79.	2.8	112
70	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer's and Dementia, 2017, 13, 168-177.	0.8	110
71	A Prospective Study of Chronic Obstructive Pulmonary Disease and the Risk for Mild Cognitive Impairment. JAMA Neurology, 2014, 71, 581.	9.0	109
72	Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2008, 16, 883-892.	1.2	108

#	Article	IF	Citations
73	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	3.1	108
74	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a populationâ€based elderly cohort. Alzheimer's and Dementia, 2016, 12, 1226-1234.	0.8	107
75	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	9.0	107
76	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	10.2	104
77	Prevalence and types of sleep disturbances acutely after traumatic brain injury. Brain Injury, 2008, 22, 381-386.	1.2	102
78	Neuropsychiatric symptoms, APOE Î¼4, and the risk of incident dementia. Neurology, 2015, 84, 935-943.	1.1	101
79	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology, 2015, 84, 1433-1442.	1.1	101
80	Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556.	2.6	94
81	DTI Analyses and Clinical Applications in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 287-296.	2.6	93
82	Preeclampsia and cognitive impairment later in life. American Journal of Obstetrics and Gynecology, 2017, 217, 74.e1-74.e11.	1.3	93
83	Longitudinal, regionâ€specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, 519-528.	0.8	91
84	Sex and Gender Differences in Alzheimer's Disease Dementia. Psychiatric Times, 2018, 35, 14-17.	0.5	91
85	Decline in Weight and Incident Mild Cognitive Impairment. JAMA Neurology, 2016, 73, 439.	9.0	89
86	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.8	88
87	Depressive Symptoms Predict Incident Cognitive Impairment in Cognitive Healthy Older Women. American Journal of Geriatric Psychiatry, 2010, 18, 204-211.	1.2	87
88	Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. International Journal of Geriatric Psychiatry, 2011, 26, 364-372.	2.7	87
89	Cholesterol and Alzheimer's diseaseâ€”is there a relation?. Mechanisms of Ageing and Development, 2006, 127, 138-147.	4.6	86
90	Performance of the CogState computerized battery in the Mayo ClinicÂStudy on Aging. Alzheimer's and Dementia, 2015, 11, 1367-1376.	0.8	85

#	Article	IF	Citations
91	An Update on Blood-Based Markers of Alzheimerâ€™s Disease Using the SiMoA Platform. Neurology and Therapy, 2019, 8, 73-82.	3.2	83
92	A history of preeclampsia is associated with a risk for coronary artery calcification 3 decades later. American Journal of Obstetrics and Gynecology, 2016, 214, 519.e1-519.e8.	1.3	82
93	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	9.0	81
94	High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970. Mayo Clinic Proceedings, 2017, 92, 66-71.	3.0	81
95	Comparison of Gait Parameters forÂPredicting Cognitive Decline: TheÂMayoÂClinic Study of Aging. Journal of Alzheimer's Disease, 2016, 55, 559-567.	2.6	79
96	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	1.6	79
97	The Fornix Sign: A Potential Sign for Alzheimer's Disease Based on Diffusion Tensor Imaging. Journal of Neuroimaging, 2012, 22, 365-374.	2.0	77
98	Elevated Plasma Ceramides in Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 215-218.	1.8	74
99	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74
100	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	7.6	72
101	Factors affecting longitudinal trajectories of plasma sphingomyelins: the Baltimore Longitudinal Study of Aging. Aging Cell, 2015, 14, 112-121.	6.7	71
102	Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135.	1.1	71
103	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE Îµ4 Genotype. JAMA Neurology, 2017, 74, 332.	9.0	71
104	Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Movement Disorders, 2017, 32, 227-234.	3.9	71
105	Predictors of New-Onset Depression After Mild Traumatic Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 100-104.	1.8	70
106	Progranulin protein levels are differently regulated in plasma and CSF. Neurology, 2014, 82, 1871-1878.	1.1	70
107	Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum. Archives of Neurology, 2010, 67, 688.	4.5	69
108	When Do Î±-Synucleinopathies Start? An Epidemiological Timeline. JAMA Neurology, 2018, 75, 503.	9.0	69

#	Article	IF	Citations
109	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	9.0	69
110	Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism. JAMA Neurology, 2017, 74, 839.	9.0	68
111	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	7.6	68
112	Artificial Intelligenceâ€“Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	4.8	68
113	Demographic and clinical variables affecting midâ€•to lateâ€life trajectories of plasma ceramide and dihydroceramide species. Aging Cell, 2015, 14, 1014-1023.	6.7	67
114	Spectrum of cognition short of dementia. Neurology, 2015, 85, 1712-1721.	1.1	67
115	Levodopa-induced dyskinesia in Parkinson disease. Neurology, 2018, 91, e2238-e2243.	1.1	66
116	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	9.0	66
117	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With Î²-Amyloidosis. JAMA Neurology, 2013, 70, 1030.	9.0	65
118	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 573-581.	2.6	65
119	Diffusion Tensor Imaging of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimerâ€™s Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 484-488.	1.8	63
120	Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S70-6.	2.2	63
121	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	4.2	63
122	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.1	62
123	Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology, 2015, 84, 1854-1861.	1.1	61
124	Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI. Neurology, 2019, 93, e1881-e1889.	1.1	59
125	COSMIC (Cohort Studies of Memory in an International Consortium): An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. BMC Neurology, 2013, 13, 165.	1.8	58
126	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.8	58

#	Article	IF	Citations
127	Chronic Obstructive Pulmonary Disease and Association With Mild Cognitive Impairment: The Mayo Clinic Study of Aging. Mayo Clinic Proceedings, 2013, 88, 1222-1230.	3.0	57
128	Cerebrospinal fluid sphingolipids, Î²-amyloid, and tau in adults at risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2486-2494.	3.1	57
129	Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. Aids, 2015, 29, 559-569.	2.2	56
130	Preeclampsia and ESRD: The Role of Shared Risk Factors. American Journal of Kidney Diseases, 2017, 69, 498-505.	1.9	56
131	Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods. Advanced Drug Delivery Reviews, 2020, 159, 232-244.	13.7	56
132	Differential effects of response-contingent and response-independent nicotine in rats. European Journal of Pharmacology, 2000, 402, 231-240.	3.5	55
133	The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimerâ€™s Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. Journal of Alzheimer's Disease, 2017, 60, 819-828.	2.6	55
134	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.1	55
135	Lipids and the pathogenesis of Alzheimer's disease: Is there a link?. International Review of Psychiatry, 2006, 18, 173-186.	2.8	54
136	Cortical Î²-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. Translational Psychiatry, 2019, 9, 123.	4.8	54
137	A lipid storageâ€“like disorder contributes to cognitive decline in HIV-infected subjects. Neurology, 2013, 81, 1492-1499.	1.1	53
138	Subtle gait changes in patients with REM sleep behavior disorder. Movement Disorders, 2013, 28, 1847-1853.	3.9	53
139	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.1	53
140	Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause. Biology of Sex Differences, 2013, 4, 6.	4.1	52
141	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251.	1.0	52
142	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Annals of Neurology, 2017, 81, 871-882.	5.3	51
143	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	3.1	51
144	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	5.3	49

#	Article	IF	Citations
145	Burden and management of type 2 diabetes in rural United States. Diabetes/Metabolism Research and Reviews, 2021, 37, e3410.	4.0	49
146	Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimerâ€™s disease?. Clinical Lipidology, 2012, 7, 525-536.	0.4	47
147	Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology, 2014, 82, 70-76.	1.1	47
148	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117.	2.3	47
149	Sex and gender in Alzheimer's disease â€“ Does it matter?. Alzheimer's and Dementia, 2018, 14, 1101-1103.	0.8	46
150	Influence of amyloid and APOE on cognitive performance in a late middleâ€aged cohort. Alzheimer's and Dementia, 2016, 12, 281-291.	0.8	45
151	Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. International Journal of Geriatric Psychiatry, 2014, 29, 153-159.	2.7	44
152	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	2.4	44
153	Association between Various Brain Pathologies and Gait Disturbance. Dementia and Geriatric Cognitive Disorders, 2017, 43, 128-143.	1.5	44
154	Comparison of Conventional ELISA with Electrochemiluminescence Technology for Detection of Amyloid-Î² in Plasma. Journal of Alzheimer's Disease, 2010, 21, 769-773.	2.6	43
155	Association of Dual Decline in Memory and Gait Speed With Risk for Dementia Among Adults Older Than 60 Years. JAMA Network Open, 2020, 3, e1921636.	5.9	43
156	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNFÎ± and Cognitive Outcomes in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1289-1295.	3.6	42
157	Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 45, 1237-1245.	2.6	41
158	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journal of the American Geriatrics Society, 2017, 65, 792-799.	2.6	41
159	Association of Apolipoprotein E Ê›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909.	5.9	41
160	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2019, 15, 878-887.	0.8	41
161	Multi-Modal MRI Analysis with Disease-Specific Spatial Filtering: Initial Testing to Predict Mild Cognitive Impairment Patients Who Convert to Alzheimer?s Disease. Frontiers in Neurology, 2011, 2, 54.	2.4	40
162	Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2013, 28, 149-154.	2.7	40

#	Article	IF	Citations
163	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	2.0	40
164	Carotid Artery Intima-Media Thickness and Subclinical Atherosclerosis in Women With Remote Histories of Preeclampsia: Results From a Rochester Epidemiology Project-Based Study and Meta-analysis. Mayo Clinic Proceedings, 2017, 92, 1328-1340.	3.0	40
165	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877.	5.3	40
166	The Mutation Matters: <scp>CSF</scp> Profiles of <scp>GCase</scp>, Sphingolipids, Î±â€Synuclein in <scp>PD_{GBA}</scp>. Movement Disorders, 2021, 36, 1216-1228.	3.9	40
167	Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study. International Psychogeriatrics, 2012, 24, 1561-1570.	1.0	39
168	Effects of Food and Drug Administrationâ€approved medications for Alzheimer's disease on clinical progression. Alzheimer's and Dementia, 2012, 8, 180-187.	0.8	39
169	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	2.0	39
170	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.8	38
171	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. Neurology, 2019, 93, e548-e558.	1.1	38
172	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	3.3	38
173	Interaction Between Vascular Factors and the APOE Îµ4 Allele in Predicting Rate of Progression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 127-134.	2.6	36
174	Evaluation of the Effect of Systolic Blood Pressure and Pulse Pressure on Cognitive Function: The Women's Health and Aging Study II. PLoS ONE, 2011, 6, e27976.	2.5	36
175	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 1609-1616.	2.6	35
176	Loss of Ovarian Hormones and Accelerated Somatic and Mental Aging. Physiology, 2018, 33, 374-383.	3.1	35
177	Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. Alzheimer's and Dementia, 2022, 18, 2707-2724.	0.8	35
178	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	3.0	34
179	Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. Journal of NeuroVirology, 2018, 24, 16-27.	2.1	34
180	Pâ€tau/AÎ²42 and AÎ²42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12190.	2.4	34

#	Article	IF	Citations
181	Caloric Intake, Aging, and Mild Cognitive Impairment: A Population-Based Study. Journal of Alzheimer's Disease, 2013, 34, 501-507.	2.6	33
182	Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2018, 63, 149-155.	2.6	33
183	Future prospects and challenges for Alzheimer's disease drug development in the era of the NIAâ€AA Research Framework. Alzheimer's and Dementia, 2018, 14, 532-534.	0.8	33
184	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30â€“91 Years and the Importance of Adjusting for Sex. Journal of the International Neuropsychological Society, 2021, 27, 211-226.	1.8	33
185	Apolipoprotein E genotype and lifetime cognitive decline. International Psychogeriatrics, 2008, 20, 109-123.	1.0	32
186	Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment. Archives of Neurology, 2011, 68, 113.	4.5	32
187	Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160.	5.3	32
188	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	6.2	32
189	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.1	31
190	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	5.3	31
191	Epidemiology and Natural History of Inclusion Body Myositis. Neurology, 2021, 96, e2653-e2661.	1.1	31
192	Circulating ceramides are inversely associated with cardiorespiratory fitness in participants aged 54â€“96Âyears from the Baltimore Longitudinal Study of Aging. Aging Cell, 2016, 15, 825-831.	6.7	30
193	Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). BMJ Open, 2017, 7, e018861.	1.9	30
194	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2018, 66, 68-74.	3.1	30
195	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1244-1250.	3.6	30
196	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	3.0	30
197	Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12291.	2.4	30
198	Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. Journal of NeuroVirology, 2010, 16, 445-456.	2.1	29

#	Article	IF	Citations
199	Early-Onset Parkinsonism and Early-Onset Parkinsonâ€™s Disease: A Population-Based Study (2010-2015). Journal of Parkinson's Disease, 2021, 11, 1197-1207.	2.8	29
200	Baseline Serum Cholesterol Is Selectively Associated With Motor Speed and Not Rates of Cognitive Decline: The Women's Health and Aging Study II. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 619-624.	3.6	28
201	Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers. journal of applied laboratory medicine, The, 2020, 5, 158-169.	1.3	28
202	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.1	28
203	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. Alzheimer's and Dementia, 2022, 18, 635-644.	0.8	28
204	Physical Activity Participation by Presence and Type of Functional Deficits in Older Women: The Women's Health and Aging Studies. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 1171-1176.	3.6	27
205	Incidence of Dementia Among Participants and Nonparticipants in a Longitudinal Study of Cognitive Aging. American Journal of Epidemiology, 2014, 180, 414-423.	3.4	27
206	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology, 2016, 86, 2077-2084.	1.1	27
207	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	3.1	27
208	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. Neurobiology of Aging, 2020, 96, 176-183.	3.1	27
209	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	9.0	27
210	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.8	26
211	Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. Journal of NeuroVirology, 2010, 16, 445-456.	2.1	26
212	Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment. JAMA Network Open, 2021, 4, e2131448.	5.9	26
213	Caregiver Assessment of Patients' Depression in Alzheimer Disease: Longitudinal Analysis in a Drug Treatment Study. American Journal of Geriatric Psychiatry, 2005, 13, 822-826.	1.2	25
214	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the populationâ€based Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2018, 33, 1114-1120.	2.7	25
215	Population-Based Evaluation of Lumbar Puncture Opening Pressures. Frontiers in Neurology, 2019, 10, 899.	2.4	25
216	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology, 2020, 94, e15-e29.	1.1	25

#	Article	IF	Citations
217	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimerâ€™s Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 76, 261-274.	2.6	25
218	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	3.4	25
219	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. American Journal of Geriatric Psychiatry, 2021, 29, 179-191.	1.2	25
220	Transition to Nursing Home From Assisted Living Is not Associated With Dementia or Dementia-Related Problem Behaviors. Journal of the American Medical Directors Association, 2006, 7, 73-78.	2.5	24
221	Slowing gait speed precedes cognitive decline by several years. Alzheimer's and Dementia, 2022, 18, 1667-1676.	0.8	24
222	Diffusion Tensor Imaging Atlas-Based Analyses in Major Depression After Mild Traumatic Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 309-315.	1.8	23
223	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	9.0	23
224	Timing of Physical Activity, Apolipoprotein E Îµ4 Genotype, and Risk of Incident Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2016, 64, 2479-2486.	2.6	23
225	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	2.6	23
226	Impact of a History of Hypertension in Pregnancy on Later Diagnosis of Atrial Fibrillation. Journal of the American Heart Association, 2018, 7, .	3.7	23
227	Sexâ€related differences in the prevalence of cognitive impairment among overweight and obese adults with type 2 diabetes. Alzheimer's and Dementia, 2018, 14, 1184-1192.	0.8	23
228	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.1	22
229	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. Journal of Alzheimer's Disease, 2018, 64, 281-290.	2.6	22
230	Hematologic Risk Factors of Vascular Disease and Their Relation to Dementia. Dementia and Geriatric Cognitive Disorders, 2006, 21, 335-352.	1.5	21
231	Plasma sphingolipids and depressive symptoms in coronary artery disease. Brain and Behavior, 2017, 7, e00836.	2.2	21
232	A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among communityâ€dwelling Mexican Americans and nonâ€Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimer's and Dementia, 2022, 18, 77-87.	0.8	21
233	Low Serum Potassium in Mid Life Associated with Decreased Cerebrospinal Fluid AÎ²42 in Late Life. Alzheimer Disease and Associated Disorders, 2006, 20, 30-36.	1.3	20
234	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	3.1	20

#	Article	IF	Citations
235	Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*. Critical Care Medicine, 2019, 47, 1116-1124.	0.9	20
236	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2020, 16, 1013-1022.	0.8	20
237	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.8	20
238	Anthropometric measures and cognition in middle-aged HIV-infected and uninfected women. The Womenâ€™s Interagency HIV Study. Journal of NeuroVirology, 2013, 19, 574-585.	2.1	19
239	Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. Journal of Hypertension, 2017, 35, 2479-2485.	0.5	19
240	Clinicopathologic discrepancies in a populationâ€based incidence study of parkinsonism in olmsted county: 1991â€2010. Movement Disorders, 2017, 32, 1439-1446.	3.9	19
241	Plasma Sphingolipids are Associated With Gait Parameters in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 960-965.	3.6	19
242	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.1	19
243	Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. International Psychogeriatrics, 2008, 20, 871-89.	1.0	18
244	Atlas-Based Diffusion Tensor Imaging Correlates of Executive Function. Journal of Alzheimer's Disease, 2015, 44, 585-598.	2.6	18
245	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.1	18
246	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. Neurology, 2020, 94, e1571-e1579.	1.1	18
247	Association of Hospitalization with Longâ€Term Cognitive Trajectories in Older Adults. Journal of the American Geriatrics Society, 2021, 69, 660-668.	2.6	18
248	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48.	5.2	18
249	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.8	18
250	Cognitive impairment and World Trade Centre-related exposures. Nature Reviews Neurology, 2022, 18, 103-116.	10.1	18
251	Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline. Neurology, 2022, 98, .	1.1	18
252	A Lipidomics Approach to Assess theÂAssociation Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature forÂCognitive Response to Exercise. Journal of Alzheimer's Disease, 2017, 60, 829-841.	2.6	17

#	Article	IF	Citations
253	Deep Learning Prediction of Mild Cognitive Impairment using Electronic Health Records. , 2019, 2019, 799-806.		17
254	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	5.3	17
255	Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study. BMC Geriatrics, 2013, 13, 135.	2.7	16
256	Peripheral sphingolipids are associated with variation in white matter microstructure in older adults. Neurobiology of Aging, 2016, 43, 156-163.	3.1	16
257	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 60-66.	1.8	16
258	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 877-883.	3.6	16
259	Association Between Sphingolipids and Cardiopulmonary Fitness in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 671-679.	3.6	16
260	CERTL reduces C16 ceramide, amyloid-Î² levels, and inflammation in a model of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 45.	6.2	16
261	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2021, 36, 1362-1369.	2.7	16
262	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 T	0.8	16
263	Computational drug repurposing based on electronic health records: a scoping review. Npj Digital Medicine, 2022, 5, .	10.9	16
264	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048.	1.1	15
265	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study ofÂAging. Journal of Alzheimer's Disease, 2017, 58, 1273-1281.	2.6	15
266	Incidence and Trends of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Population-Based Study. Journal of Parkinson's Disease, 2020, 10, 179-184.	2.8	15
267	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	4.2	15
268	Caregiver Assessment of Patients' Depression in Alzheimer Disease: Longitudinal Analysis in a Drug Treatment Study. American Journal of Geriatric Psychiatry, 2005, 13, 822-826.	1.2	15
269	Pregnancy history and blood-borne microvesicles in middle aged women with and without coronary artery calcification. Atherosclerosis, 2016, 253, 150-155.	0.8	14
270	Electronic Algorithm Is Superior to Hospital Discharge Codes for Diagnoses of Hypertensive Disorders of Pregnancy in Historical Cohorts. Mayo Clinic Proceedings, 2018, 93, 1707-1719.	3.0	14

#	Article	IF	Citations
271	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. British Journal of Anaesthesia, 2020, 124, 594-602.	3.4	14
272	CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267.	1.1	14
273	Building a framework for inclusion in health services research: Development of and pre-implementation faculty and staff attitudes toward the Diversity, Equity, and Inclusion (DEI) plan at Mayo Clinic. Journal of Clinical and Translational Science, 2021, 5, e88.	0.6	14
274	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	5.2	14
275	A â€˜birdâ€™s eyeâ€™ view on the current status and potential benefits of blood biomarkers for Parkinsonâ€™s disease. Biomarkers in Medicine, 2014, 8, 225-227.	1.4	13
276	Leptin, Adiponectin and Cognition in Middle-aged HIV-infected and Uninfected Women. The Brooklyn Womenâ€™s Interagency HIV Study. Journal of Gerontology & Geriatric Research, 2015, 04, .	0.1	13
277	Trajectories of plasma IGF-1, IGFBP-3, and their ratio in the Mayo Clinic Study of Aging. Experimental Gerontology, 2018, 106, 67-73.	2.8	13
278	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. Age and Ageing, 2019, 48, 888-894.	1.6	13
279	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. British Journal of Anaesthesia, 2019, 123, 808-817.	3.4	13
280	Cognitive function after surgery with regional or general anesthesia: A populationâ€based study. Alzheimer's and Dementia, 2019, 15, 1243-1252.	0.8	13
281	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. Clinical Neuropsychologist, 2019, 33, 1102-1126.	2.3	13
282	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076.	3.3	13
283	Association of Midlife Plasma Amyloid-Î² Levels With Cognitive Impairment in Late Life. Neurology, 2021, 97, e1123-e1131.	1.1	13
284	Sphingolipids in Alzheimerâ€™s Disease and Related Disorders. Journal of Alzheimer's Disease, 2017, 60, 753-756.	2.6	12
285	Risk factors of neurovascular ageing in women. Journal of Neuroendocrinology, 2020, 32, e12777.	2.6	12
286	Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159.	3.3	12
287	Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt <scp>Alphaâ€Synucleinopathies</scp>. Annals of Neurology, 2021, 89, 293-303.	5.3	12
288	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 79, 377-388.	2.6	12

#	Article	IF	Citations
289	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	3.3	12
290	Traumatic Brain Injury and Risk of Alzheimerâ€™s Disease and Related Dementias in the Population. Journal of Alzheimer's Disease, 2022, 88, 1049-1059.	2.6	12
291	Association of neighborhood socioeconomic disadvantage and cognitive impairment. Alzheimer's and Dementia, 2023, 19, 761-770.	0.8	12
292	Rates of Depression in Individuals With Pathologic But Not Clinical Alzheimer Disease are Lower Than Those in Individuals Without the Disease: Findings From the Baltimore Longitudinal Study on Aging (BLSA). Alzheimer Disease and Associated Disorders, 2007, 21, 199-204.	1.3	11
293	Interictal, circulating sphingolipids in women with episodic migraine. Neurology, 2015, 85, 1214-1223.	1.1	11
294	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.8	11
295	Knowledge gaps in Alzheimer's disease immune biomarker research. Alzheimer's and Dementia, 2021, 17, 2030-2042.	0.8	11
296	Trends in incidence of dementia among patients with rheumatoid arthritis: A population-based cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 853-857.	3.4	11
297	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	3.3	11
298	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. Acta Neuropathologica, 2022, 144, 1117-1125.	7.7	11
299	Personality Changes in Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E14-E14.	1.8	10
300	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281.	2.6	10
301	Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study. Maturitas, 2018, 117, 64-77.	2.4	10
302	Ceramide Accumulation Is Associated with Declining Verbal Memory in Coronary Artery Disease Patients: An Observational Study. Journal of Alzheimer's Disease, 2018, 64, 1235-1246.	2.6	10
303	Early temporal characteristics of elderly patient cognitive impairment in electronic health records. BMC Medical Informatics and Decision Making, 2019, 19, 149.	3.0	10
304	Higher vitamin B12 level at Parkinson's disease diagnosis is associated with lower risk of future dementia. Parkinsonism and Related Disorders, 2020, 73, 19-22.	2.2	10
305	Traumatic brain injury preceding clinically diagnosed Î±-synucleinopathies. Neurology, 2020, 94, e764-e773.	1.1	10
306	Improving clinical outcomes through attention to sex and hormones in research. Nature Reviews Endocrinology, 2021, 17, 625-635.	9.6	10

#	Article	IF	Citations
307	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.1	10
308	A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population. International Journal of Environmental Research and Public Health, 2021, 18, 681.	2.6	10
309	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE Îµ4 genotype status: the Mayo Clinic Study of Aging. European Journal of Ageing, 2019, 16, 491-502.	2.8	9
310	Identifying incident Parkinson's disease using administrative diagnostic codes: a validation study. Clinical Parkinsonism & Related Disorders, 2020, 3, 100061.	0.9	9
311	Association of Cortical and Subcortical Î²-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 64-71.	1.8	9
312	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12141.	2.4	9
313	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	2.0	9
314	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	3.1	9
315	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. NeuroImage, 2022, 251, 119020.	4.2	9
316	Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. Aids, 2017, 31, 1365-1378.	2.2	8
317	Practical algorithms for amyloid Î² probability in subjective or mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 710-720.	2.4	8
318	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volumeâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2431-2436.	2.4	8
319	Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2019, 33, 68-71.	1.3	8
320	Association of Premenopausal Bilateral Oophorectomy With Restless Legs Syndrome. JAMA Network Open, 2021, 4, e2036058.	5.9	8
321	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	2.6	8
322	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. Journal of Alzheimer's Disease, 2021, 83, 1269-1279.	2.6	8
323	Incidence and prevalence of immuneâ€mediated necrotizing myopathy in adults in Olmsted County, Minnesota. Muscle and Nerve, 2022, 65, 541-546.	2.2	8
324	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12299.	2.4	8

#	Article	IF	Citations
325	Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinsonâ€™s Disease (1991â€“2010). Journal of Parkinson's Disease, 2022, 12, 1319-1327.	2.8	8
326	Time Trends in Unilateral and Bilateral Oophorectomy in a Geographically Defined American Population. Obstetrics and Gynecology, 2022, 139, 724-734.	2.4	8
327	Causal structure discovery identifies risk factors and early brain markers related to evolution of white matter hyperintensities. NeuroImage: Clinical, 2022, 35, 103077.	2.7	8
328	Erectile Dysfunction Preceding Clinically Diagnosed Î±-Synucleinopathies: A Case-Control Study in Olmsted County. Parkinson's Disease, 2019, 2019, 1-6.	1.1	7
329	Plasma Metabolites Associated with Brain MRI Measures of Neurodegeneration in Older Adults in the Atherosclerosis Risk in Communitiesâ€“Neurocognitive Study (ARIC-NCS). International Journal of Molecular Sciences, 2019, 20, 1744.	4.1	7
330	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2019, 79, 43-49.	3.1	7
331	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2785-2793.	2.4	7
332	Brain MRI after critical care admission: A longitudinal imaging study. Journal of Critical Care, 2021, 62, 117-123.	2.2	7
333	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimerâ€™s Disease Based on Cogstate One Card Learning Accuracy Performance. Journal of Alzheimer's Disease, 2021, 83, 861-877.	2.6	7
334	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	3.1	7
335	Inflammatory biomarkers, multi-morbidity, and biologic aging. Journal of International Medical Research, 2022, 50, 030006052211093.	1.0	7
336	Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE Îµ4 Allele. Frontiers in Aging Neuroscience, 2015, 7, 172.	3.4	6
337	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a populationâ€based sample. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 127-130.	2.4	6
338	Characterization of intravascular cellular activation in relationship to subclinical atherosclerosis in postmenopausal women. PLoS ONE, 2017, 12, e0183159.	2.5	6
339	New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia. Alzheimer's and Dementia, 2018, 14, 703-706.	0.8	6
340	Risk of de novo cancer after premenopausal bilateral oophorectomy. American Journal of Obstetrics and Gynecology, 2022, 226, 539.e1-539.e16.	1.3	6
341	Poly (ADP-Ribose) and Î±â€“synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	2.5	6
342	Artificial Intelligenceâ€“Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	3.0	6

#	Article	IF	Citations
343	Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity. Frontiers in Aging Neuroscience, 0, 14, .	3.4	6
344	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	3.0	5
345	Plasma Sphingolipids Mediate a Relationship Between Type 2 Diabetes and Memory Outcomes in Patients with Coronary Artery Disease Undertaking Exercise. Journal of Alzheimer's Disease, 2019, 69, 717-727.	2.6	5
346	Anesthesia With and Without Nitrous Oxide and Long-term Cognitive Trajectories in Older Adults. Anesthesia and Analgesia, 2020, 131, 594-604.	2.2	5
347	Effect of menopausal hormone therapy on proteins associated with senescence and inflammation. Physiological Reports, 2020, 8, e14535.	1.7	5
348	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	2.4	5
349	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. German Journal of Exercise and Sport Research, 2021, 51, 487-494.	1.2	5
350	Association of plasma ceramides with prevalent and incident type 2 diabetes mellitus in middle and older aged adults. Diabetes Research and Clinical Practice, 2021, 179, 108991.	2.8	5
351	Women who participated in the paid labor force have lower rates of memory decline. Neurology, 2020, 95, 1027-1028.	1.1	5
352	Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	5
353	Population-Based Prevalence of Infarctions on 3D Fluid-Attenuated Inversion Recovery (FLAIR) Imaging. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106583.	1.6	5
354	Vascular diseases: One pathway toward new conceptual models of dementia. Alzheimer's and Dementia, 2012, 8, S69-70.	0.8	4
355	Ghrelin, Amylin, Gastric Inhibitory Peptide and Cognition in Middle-Aged HIV-Infected and Uninfected Women: The Womenâ€™s Interagency HIV Study. Journal of Neurology & Neurophysiology, 2017, 08, .	0.1	4
356	Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism. Mayo Clinic Proceedings, 2019, 94, 1825-1831.	3.0	4
357	Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial). Trials, 2020, 21, 19.	1.6	4
358	Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2020, 34, 118-121.	1.3	4
359	Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia. Neurology: Clinical Practice, 2020, 10, 156-161.	1.6	4
360	Peripheral Markers of Neurovascular Unit Integrity and Amyloid-Î² in the Brains of Menopausal Women. Journal of Alzheimer's Disease, 2021, 80, 397-405.	2.6	4

#	Article	IF	Citations
361	Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimerâ€™s Disease in the FIT-AD Trial. Journal of Alzheimer's Disease Reports, 2021, 5, 601-611.	2.2	4
362	What about sex?. Nature Metabolism, 2021, 3, 1586-1588.	11.9	4
363	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	2.6	4
364	CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200.	3.1	4
365	Relationships of Cerebral Perfusion With Gait Speed Across Systolic Blood Pressure Levels and Age: A Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 514-520.	3.6	4
366	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldtâ€“Jakob disease and autoimmune encephalitis. European Journal of Neurology, 2022, 29, 2905-2912.	3.3	4
367	Biomarker development: A population-level perspective. , 2012, 8, 247-249.		3
368	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2020, 78, 911-917.	2.6	3
369	Infections or Sepsis Preceding Clinically Diagnosed Î±â€Synucleinopathies : A Caseâ€Control Study. Movement Disorders, 2020, 35, 1684-1689.	3.9	3
370	Brain amyloid, cortical thickness, and changes in activities of daily living. Annals of Clinical and Translational Neurology, 2020, 7, 474-485.	3.7	3
371	Association between surgery with anesthesia and cognitive decline in older adults: Analysis using shared parameter models for informative dropout. Journal of Clinical and Translational Science, 2021, 5, e27.	0.6	3
372	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 81, 533-543.	2.6	3
373	Association of Performance on the Financial Capacity Instrumentâ€“Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. Neurology: Clinical Practice, 2022, 12, 113-124.	1.6	3
374	Early Alert of Elderly Cognitive Impairment using Temporal Streaming Clustering. , 2021, 2021, 905-912.		3
375	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	7.7	3
376	P3â€443: ACCELERATED FAILURE TIME AS A MODEL FOR AMYLOID AND TAU ACCUMULATION. Alzheimer's and Dementia, 2018, 14, P1285.	0.8	1
377	Orthostatic Hypotension as a Prodromal Marker of Î±-Synucleinopathiesâ€”Reply. JAMA Neurology, 2018, 75, 1155.	9.0	1
378	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451.	1.6	1

#	Article	IF	Citations
379	P4â€537: DETECTION OF ALZHEIMER'S DISEASE IN CSF USING AUTOMATED ASSAYS FOR CLASSICAL CSF BIOMARKERS. Alzheimer's and Dementia, 2019, 15, P1521.	0.8	1
380	Comparison of cerebrospinal fluid phosphorylated tau 181 and 217 for cognitive progression. Alzheimer's and Dementia, 2020, 16, e040503.	0.8	1
381	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, e272-e280.	3.6	1
382	Risk Factors and Wellness Measures Associated with Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus in Hispanic Adults. Metabolic Syndrome and Related Disorders, 2021, 19, 180-189.	1.3	1
383	Medical and nursing home costs: From cognitively unimpaired through dementia. Alzheimer's and Dementia, 2021, , .	0.8	1
384	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2020, 93, 52-54.	3.1	1
385	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	2.4	1
386	Cohort profile: the Olmsted County hypertensive disorders of pregnancy (HDP) cohort using the Rochester Epidemiology Project. BMJ Open, 2022, 12, e055057.	1.9	1
387	Long-Term Risk of Stroke after Traumatic Brain Injury: A Population-Based Medical Record Review Study. Neuroepidemiology, 2022, 56, 283-290.	2.3	1
388	Prediction of Incident Dementia Using Patient Temporal Health Status. Studies in Health Technology and Informatics, 2022, , .	0.3	1
389	Shifting our focus to blood-based biomarkers of Alzheimerâ€™s disease: the promise of ceramides and sphingomyelins. Neurodegenerative Disease Management, 2012, 2, 91-94.	2.2	0
390	Focusing on the fornix: can fornix diffusion tensor imaging measures be used to predict Alzheimerâ€™s disease?. Neurodegenerative Disease Management, 2012, 2, 549-551.	2.2	0
391	Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia. International Journal of Alzheimer's Disease, 2013, 2013, 1-2.	2.0	0
392	Is Exercise in Early- and Mid-Adulthood Associated With Cognition in Mid-Life?. American Journal of Geriatric Psychiatry, 2014, 22, S102-S103.	1.2	0
393	P4-089: SELF- AND INFORMANT-RATED DAILY FUNCTION IS ASSOCIATED WITH AMYLOID AND NEURODEGENERATIVE IMAGING IN COGNITIVELY NORMAL INDIVIDUALS. , 2014, 10, P816-P816.		0
394	P2-167: Influence of amyloid and APOE genotype on cognitive performance in a middle-aged cohort. , 2015, 11, P553-P553.		0
395	S1-01-02: Differences Between Men and Women in the Risk of Dementia. , 2016, 12, P161-P161.		0
396	Overall Survival and Causes of Death in Neurodegenerationâ€"An Overlooked and Underreported Themeâ€"Reply. JAMA Neurology, 2017, 74, 1379.	9.0	0

#	Article	IF	Citations
397	Neurofilaments in blood. Neurology, 2017, 89, 2126-2127.	1.1	0
398	[P3â€“242]: PLASMA TOTAL TAU, COGNITIVE DECLINE, AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2017, 13, P1032.	0.8	0
399	P2â€491: SUBTLE COGNITIVE DYSFUNCTION ON COGSTATE IS ASSOCIATED WITH BIOMARKER POSITIVE STATUS. Alzheimer's and Dementia, 2018, 14, P917.	0.8	0
400	ICâ€Pâ€116: COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION. Alzheimer's and Dementia, 2018, 14, P99.	0.8	0
401	P3â€221: LONGITUDINAL ASSOCIATION BETWEEN PHOSPHATIDYLCHOLINES, NEUROIMAGING MEASURES OF ALZHEIMER'S DISEASE PATHOPHYSIOLOGY, AND COGNITION IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1156.	0.8	0
402	P3â€238: LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOIDâ€PET, FDGâ€PET, AND COGNITION AMONG NONâ€DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1163.	0.8	0
403	P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P782.	0.8	0
404	F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. Alzheimer's and Dementia, 2018, 14, P603.	0.8	0
405	O2â€13â€01: INCIDENCE OF CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P652.	0.8	0
406	FTS4â€01â€04: CHALLENGES IN USING CSF BIOMARKERS FOR OPERATIONALIZING THE NIAâ€AA AD RESEARCH FRAMEWORK. Alzheimer's and Dementia, 2018, 14, P1399.	0.8	0
407	P1â€624: SEXâ€RELATED DIFFERENCES IN COGNITIVE IMPAIRMENT AMONG OVERWEIGHT AND OBESE ADULTS WITH TYPE 2 DIABETES. Alzheimer's and Dementia, 2018, 14, P579.	0.8	0
408	P1â€414: STATINS AND BRAIN HEALTH: MEDICATION EFFECTS ON NEUROIMAGING BIOMARKERS IN OLDER INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P463.	0.8	0
409	P3â€597: MEDIAL TEMPORAL LOBE NEURODEGENERATION OBSERVED IN WOMEN WHO UNDERWENT BILATERAL OOPHORECTOMY BEFORE THE ONSET OF MENOPAUSE. Alzheimer's and Dementia, 2018, 14, P1356.	0.8	0
410	O2â€04â€05: CSF BIOMARKERS IN THE GENERAL POPULATION: ASSOCIATIONS WITH DEMOGRAPHICS AND APOE GENOTYPE. Alzheimer's and Dementia, 2018, 14, P624.	0.8	0
411	T188. Ceramide Accumulation is Associated With Declining Verbal Memory in Coronary Artery Disease Patients. Biological Psychiatry, 2018, 83, S201.	1.3	0
412	P2â€407: COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION. Alzheimer's and Dementia, 2018, 14, P863.	0.8	0
413	DUAL DECLINE IN MEMORY AND GAIT UNIQUELY IDENTIFIES OLDER PERSONS AT HIGH RISK OF DEMENTIA. Innovation in Aging, 2019, 3, S586-S586.	0.1	0
414	ICâ€Pâ€086: CORTICAL ATROPHY PATTERNS OF EMPIRICALLY DERIVED INCIDENT MCI SUBTYPES IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2019, 15, P76.	0.8	0

#	Article	IF	Citations
415	ICâ€Pâ€059: APOE AND EDUCATION: EFFECTS ON REGIONAL TAU AND FDG METABOLISM IN OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P58.	0.8	0
416	Medical Doctors and Dementia: A Longitudinal Study. Journal of the American Geriatrics Society, 2020, 68, 1250-1255.	2.6	0
417	Exposure to surgery with regional anesthesia and cortical thickness in older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12012.	3.7	0
418	Sex differences in CSF biomarkers of Alzheimerâ€™s disease. , 2021, , 107-123.		0
419	Late-life Physical Exercise, Neuropsychiatric Symptoms And The Risk Of Incident Mild Cognitive Impairment. Medicine and Science in Sports and Exercise, 2020, 52, 339-340.	0.4	0
420	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 304-313.	3.6	0
421	Correlates of neuroimaging measures with pathological scales of cerebrovascular disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
422	Future use and implementation of AD blood biomarkers from a clinical and epidemiological perspective. Alzheimer's and Dementia, 2021, 17, .	0.8	0
423	Diffusion models reveal white matter microstructural changes with aging, pathology, and cognition. Alzheimer's and Dementia, 2021, 17, .	0.8	0
424	Successful cognitive aging definitions and associated demographic, biomarker profiles and lifestyles in the 80+ MCSA population. Alzheimer's and Dementia, 2021, 17, .	0.8	0